Kedrion Biopharma

Kedrion Biopharma is a plasma-derived biopharmaceutical company that produces therapies for rare diseases, including primary and secondary immunodeficiencies. The company is investing €150 million to triple its production capacity in Italy's 'Plasma Valley' to treat rare diseases.

AI named Kedrion Biopharma from October 2025 to July 2026.